ValuEngine lowered shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a report issued on Friday morning.

XOMA has been the subject of a number of other reports. Zacks Investment Research raised shares of XOMA from a sell rating to a buy rating and set a $27.00 price target for the company in a research note on Wednesday, May 16th. S&P Equity Research reduced their price target on shares of XOMA from $18.74 to $16.26 in a research note on Tuesday, August 14th. Cowen reaffirmed a hold rating on shares of XOMA in a research note on Thursday, May 10th. HC Wainwright set a $49.00 price target on shares of XOMA and gave the stock a buy rating in a research note on Thursday, May 10th. Finally, Wedbush reaffirmed an outperform rating and issued a $33.00 price target on shares of XOMA in a research note on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. XOMA presently has a consensus rating of Hold and a consensus price target of $31.32.

Shares of NASDAQ:XOMA opened at $17.17 on Friday. The company has a market capitalization of $147.61 million, a PE ratio of 17.52 and a beta of 2.48. XOMA has a twelve month low of $15.35 and a twelve month high of $37.25. The company has a quick ratio of 12.46, a current ratio of 12.46 and a debt-to-equity ratio of 3.06.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The company had revenue of $2.26 million during the quarter, compared to analyst estimates of $4.57 million. XOMA had a return on equity of 379.39% and a net margin of 43.55%. equities analysts forecast that XOMA will post -0.89 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XOMA. GSA Capital Partners LLP bought a new stake in shares of XOMA in the 1st quarter worth approximately $243,000. Allianz Asset Management GmbH raised its holdings in shares of XOMA by 32.7% in the 1st quarter. Allianz Asset Management GmbH now owns 12,245 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 3,020 shares in the last quarter. Tibra Equities Europe Ltd bought a new stake in shares of XOMA in the 1st quarter worth approximately $283,000. ClariVest Asset Management LLC bought a new stake in shares of XOMA in the 1st quarter worth approximately $380,000. Finally, Dynamic Technology Lab Private Ltd raised its holdings in shares of XOMA by 57.6% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,112 shares of the biotechnology company’s stock worth $420,000 after purchasing an additional 7,349 shares in the last quarter. Institutional investors and hedge funds own 43.60% of the company’s stock.

XOMA Company Profile

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Featured Article: New Google Finance Tool and Screening Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.